Kidney Disease Associated With Anorexia Nervosa: A Case Series With Kidney Biopsies

Hirokazu Marumoto, Takaya Sasaki, Nobuo Tsuboi, Tatsuhiko Ito, Masahiro Ishikawa, Makoto Ogura, Masato Ikeda, and Takashi Yokoo

Rationale & Objective: Anorexia nervosa is often intractable and induces various physical disorders, including kidney disease and mineral disorders, occasionally progressing to kidney failure. No consensus-based clinical practice guidelines have been established for patients with anorexia nervosa referred to a nephrologist.

Study Design: Patients with anorexia nervosa–associated kidney disease diagnosed were analyzed retrospectively. Kidney outcomes were defined as doubling of serum creatinine level and/or progression to end-stage kidney disease.

Setting & Participants: Patients with a history of anorexia nervosa with kidney disease, including electrolyte abnormalities, who were referred to our hospital between 1992 and 2017 were included.

Results: 14 female patients were included. The time from anorexia nervosa onset to the initial visit with a nephrologist was 17.8 years. At the first visit, median body mass index was 13.4 kg/m², median serum creatinine level was 1.9 mg/dL, and median serum potassium level was 2.7 mmol/L. All patients showed hypokalemia and addictive vomiting or diuretic/laxative abuse. During the median observation period of 3.1 years, kidney outcomes occurred in 9 patients, and 2 died due to their anorexia nervosa. 4 patients underwent kidney biopsy. The kidney biopsy findings of these patients included hypertrophy of the juxtaglomerular apparatus, advanced glomerular collapse, and interstitial fibrosis, consistent with ischemic kidney injury and hypokalemic nephropathy.

Limitations: The sample size was small, and kidney function was assessed based on serum creatinine levels in patients with anorexia nervosa with low muscle mass.

Conclusions: Most patients with anorexia nervosa referred to nephrologists had kidney disease at the time of the first visit. Improving kidney outcomes of patients with anorexia nervosa may require earlier collaboration between psychiatrists and nephrologists.

Methods

Patient Selection

This study included patients with a history of an eating disorder complicated with kidney disease including electrolyte abnormalities referred to Jikei University Hospital, Jikei University Kashiwa Hospital, or Kawaguchiko Municipal Medical Center between January 1992 and December 2017. Patients with an eating disorder, such as anorexia nervosa and/or bulimia nervosa, who had been coded as International Classification of Disease, Ninth or Tenth Revision, were retrospectively extracted, and a definitive diagnosis of anorexia nervosa was made by a psychiatrist. Exception criteria were 18 years or younger,
Anorexia nervosa is a type of abnormal eating behavior seen mainly in young women. This study was inspired by encountering a patient with anorexia nervosa with kidney failure undergoing dialysis therapy. This study was performed to clarify the characteristics of patients with anorexia nervosa who visited the hospital to obtain care for kidney disease. In patients with anorexia nervosa, habitual vomiting or diuretic/laxative abuse may cause irreversible damage to the kidneys. Therefore, patients with anorexia nervosa require both psychiatric and physical support.

**Definition**

We defined estimated glomerular filtration rate (eGFR) following the method of the Japanese Society of Nephrology: eGFR (mL/min/1.73 m²) = 194 × creatinine⁻¹.⁰⁹⁴ × age⁻⁰.₂⁸⁷ × 0.⁷³⁹ (if female). We calculated body surface area (BSA) using the DuBois method: BSA (m²) = 0.007184 × weight (kg)⁻⁰.₄₂⁵ × height (cm)⁻⁰.₇₂⁵. Body mass index (BMI) was calculated as weight (kg) ÷ [height (m)]². A lean state was defined as BMI < 18.5 kg/m². We defined kidney disease as eGFR < 60 mL/min/1.73 m², hypokalemia as potassium level < 3.5 mmol/L, phosphorus disorder as phosphorus level > 4.5 or < 2.5 mg/dL, and calcium disorder as corrected calcium level > 10.2 or < 8.4 mg/dL. Kidney outcome was defined as a composite of doubling in serum creatinine level from baseline or progression to end-stage kidney disease (eGFR < 15 mL/min/1.73 m²). Initiation of kidney replacement therapy or death was applied as a hard outcome. All blood measurements were taken from serum samples. Patients who had a history of diuretic or laxative abuse were identified based on medical records. A history of vomiting was defined as past habitual vomiting.

**Histopathologic Analyses**

In 3 patients, kidney specimens were obtained by percutaneous needle biopsy using an 18-gauge biopsy needle. One patient underwent open biopsy, and the specimen was obtained by wedge resection. Tissues were embedded in paraffin, cut into 3- to 4-μm sections, and stained with hematoxylin and eosin, periodic acid–Schiff, Masson trichrome, and periodic acid–methenamine silver. Von Kossa staining was performed to visualize calcium deposits. The area of interstitial fibrosis and/or tubular atrophy was evaluated semi-quantitatively. The number and percentage of glomeruli affected by global glomerulosclerosis were assessed. All biopsy specimens were examined with immunostaining and electron microscopy.

**RESULTS**

**Baseline Characteristics and Kidney Outcomes**

Baseline characteristics of patients are shown in Table 1. Median age at the time of anorexia nervosa diagnosis was 19.5 [10.8, 23.5]. Median age at eating disorder onset was 13.4 [12.4, 15.1]. Median time to the first visit was 39.0 [33.3, 44.0]. Median follow-up period was 3.1 [0.7, 5.9]. Median age at the time of anorexia nervosa diagnosis was 13.4 [12.4, 15.1]. Median baseline characteristics of patients are shown in Table 1.

**Table 1. Patient Characteristics**

| Variables                                      | All Subjects (n = 14) | Variables                                      | All Subjects (n = 14) |
|------------------------------------------------|-----------------------|------------------------------------------------|-----------------------|
| Female sex                                     | 14 (100%)             | Aldosterone to renin activity ratio            | 16.9 [10.3, 38.1]     |
| Time to the first visit, y                     | 175 [10.8, 23.5]      | Plasma aldosterone concentration, pg/mL        | 128 [77, 465]         |
| Age at the first visit, y                      | 39.0 [33.3, 44.0]     | Plasma renin activity, ng/mL/h                  | 11.4 [2.3, 19.8]      |
| Age at eating disorder onset, y                | 19.5 [17.3, 26.0]     | pH                                              | 7.4 [7.4, 7.5]        |
| BMI, kg/m²                                     | 13.4 [12.4, 15.1]     | Base excess                                      | 3.2 [–6.3, 13.9]      |
| BSA, m²                                        | 1.21 [1.19, 1.33]     | $\text{PCO}_2$, mm Hg                           | 44 [40, 51]           |
| Follow-up period, y                            | 3.1 [0.7, 5.9]        | HCO₃⁻, mmol/L                                   | 27.4 [19.2, 39.6]     |
| Serum creatinine, mg/dL                        | 1.9 [1.2, 3.5]        | Urinary protein excretion, g/g Cr               | 0.14 [0.04, 0.44]     |
| eGFR, mL/min/1.73 m²                           | 20.9 [8.5, 32.2]      | Urinary β2-MG, μg/g Cr                          | 4,000 [540, 54,986]   |
| Serum urea nitrogen, mg/dL                     | 29.7 [170, 55.6]      | UG_NAG %                                        | 0.28 [0.08, 1.38]     |
| Serum sodium, mmol/L                           | 138 [136, 141]        | FE_Na %                                         | 0.28 [0.08, 1.38]     |
| Serum potassium, mmol/L                        | 2.7 [2.2, 3.1]        | Use of diuretics or laxatives                   | 7 (50%)               |
| Serum chloride, mmol/L                         | 95 [87, 100]          | Habit of vomiting                               | 13 (93%)              |
| Serum phosphorus, mg/dL                        | 3.85 [3.2, 5.17]      | Hypertension                                    | 0 (0%)                |
| Serum calcium, mg/dL                           | 9.15 [8.62, 9.57]     | Use of RAAS inhibitors                          | 0 (0%)                |
| Serum magnesium, g/dL                          | 2.30 [2.02, 2.70]     | Death                                           | 2 (14%)               |

**Note:** Values for categorical variables are given as number (percent); values for continuous variables are given as median [interquartile range]. Conversion factors for units: creatinine in mg/dL to μmol/L, × 88.4; serum urea nitrogen in mg/dL to mmol/L, × 0.357; serum calcium in mg/dL to mmol/L, × 0.2495. Abbreviations: BMI, body mass index; BSA, body surface area; Cr, creatinine; eGFR, estimated glomerular filtration rate; FE_Na, fractional excretion of sodium; MG, macroglobulin; NAG, N-acetyl-β-D-glucosaminidase; RAAS, renin-angiotensin-aldosterone system.
19.5 years, and that at the time of the first visit to a nephrologist was 39.0 years. At the time of the first visit, all patients were lean (BMI < 18.5 kg/m²). Median creatinine level was 1.9 [interquartile range, 1.2, 3.5] mg/dL, median eGFR was 20.9 [interquartile range, 8.5, 32.2] mL/min/1.73 m². Thirteen patients (93%) had hypokalemia, 6 (43%) had a phosphorus concentration disorder, and 3 (21%) had a calcium concentration disorder.

**Table 2. Comparison Between 2 Groups With or Without Kidney Outcomes and Kidney Biopsy During Follow-up**

| Variables                              | Without Kidney Outcomes (n = 5) | With Kidney Outcomes (n = 9) |
|----------------------------------------|---------------------------------|-----------------------------|
| Years to first visit to nephrologist (years) | 14 [6, 18]                      | 19 [13, 24]                 |
| Age at first visit to a nephrologist, y | 34 [33, 35]                     | 42 [37, 48]                 |
| Age at eating disorder onset, y         | 20 [17, 27]                     | 19 [18, 23]                 |
| Body weight, kg                         | 39 [35, 40]                     | 31 [27, 33]                 |
| BMI, kg/m²                              | 15.2 [14.6, 15.6]               | 12.8 [11.0, 13.9]           |
| BSA, m²                                 | 1.34 [1.26, 1.38]               | 1.19 [1.12, 1.22]           |
| Serum albumin, g/dL                     | 3.9 [3.2, 4.6]                  | 3.5 [3.4, 4.0]              |
| eGFR, mL/min/1.73 m²                    | 34.7 [27.0, 57.5]               | 13.8 [10.7, 40.4]           |
| Serum urea nitrogen, mg/dL              | 24 [11, 32]                     | 46 [20, 63]                 |
| Serum sodium, mmol/L                    | 136 [135, 138]                  | 139 [137, 141]              |
| Serum potassium, mmol/L                 | 2.6 [2.4, 2.8]                  | 2.8 [2.1, 3.1]              |
| Serum chloride, mmol/L                  | 95 [95, 99]                     | 91 [85, 100]                |
| Serum calcium, mg/dL                    | 9.2 [8.6, 9.5]                  | 9.1 [8.7, 9.6]              |
| Serum magnesium, g/dL                   | 1.95 [1.85, 2.02]               | 2.60 [2.32, 4.38]           |
| pH                                     | 7.44 [7.43, 7.45]               | 7.44 [7.25, 7.47]           |
| Base excess, mmol/L                     | 2.25 [2.75, 8.90]               | 3.20 [-12.05, 14.03]        |
| PCO₂, mm Hg                             | 43.6 [39.7, 50.9]               | 43.7 [41.4, 51.5]           |
| HCO₃⁻, mmol/L                           | 26.7 [20.8, 34.8]               | 27.4 [14.6, 39.6]           |
| ACTH, pg/mL                             | 17.9 [15.8, 20.1]               | 26.8 [20.9, 28.8]           |
| Cortisol, μg/dL                         | 150 [113, 19.7]                 | 165.5 [13.0, 17.7]          |
| Aldosterone to renin activity ratio     | 24.1 [16.2, 34.9]               | 14.7 [10.3, 34.5]           |
| Plasma aldosterone concentration, pg/mL | 128 [93, 252]                   | 130 [77, 779]               |
| Plasma renin activity, ng/mL/h          | 9.9 [2.6, 18]                   | 13 [2.7, 37]                |

During follow-up

| Follow-up, y                           | 1.8 [0.3, 3.3]                  | 4.8 [2.0, 6.0]              |
| Serum creatinine at last observation, mg/dL | 1.04 [0.93, 1.71]              | 3.65 [3.04, 4.84]           |
| eGFR at last observation, mL/min/1.73 m²  | 51.6 [27.9, 58.8]               | 12.9 [9.57, 16.2]           |
| Patient reached doubling of creatinine  | 0                               | 6                            |
| Patient reached ESKD                    | 0                               | 7                            |

Note: Values for categorical variables are given as number; values for continuous variables are given as median [interquartile range]. Conversion factors for units: creatinine in mg/dL to μmol/L, ×88.4; serum urea nitrogen in mg/dL to mmol/L, ×0.357; serum calcium in mg/dL to mmol/L, ×0.2495. Abbreviations: ACTH, adrenocorticotropic hormone; BMI, body mass index; BSA, body surface area; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease.

**Case Presentations of the 4 Patients Who Underwent Kidney Biopsy**

Four of the 14 patients underwent kidney biopsy; their characteristics and histopathology results are shown in Table 3 and Figure 1. One (patient 1) had normal kidney function, whereas the remaining 3 (patients 2, 3, and 4) had decreased kidney function at the time of biopsy. Kidney biopsy was performed in patient 1 soon after the anorexia nervosa diagnosis, and in the remaining 3 patients, it was performed after an interval of 9 to 14 years. These 4 patients were lean and had various degrees of hypokalemia. The biopsy specimen of patient 1 showed hyperplasia of the juxtaglomerular apparatus and only mild tubulointerstitial damage (Fig 1A and B). Patient 2 had approximately 50% interstitial fibrosis and/or tubular atrophy and massive infiltration of lymphocytes into the interstitium (Fig 1C and D). Based on a diagnosis of diffuse tubulointerstitial nephritis of unknown origin, oral corticosteroid therapy was administered for 6 months.
However, the therapeutic effect was not evident and creatinine level remained high (4-5 mg/dL) during the follow-up period. Patient 3 showed approximately 60% interstitial fibrosis and/or tubular atrophy (Fig 1E and F). Patient 4 underwent open kidney biopsy because the material obtained by percutaneous needle biopsy was insufficient to make a diagnosis. Light microscopy showed that 4 of 146 glomeruli were globally sclerotic and most glomeruli on the surface layer of the cortex were collapsed (Fig 1G and H). Interstitial fibrosis was observed predominantly in the subcapsular region. During the follow-up period, her decreased kidney function progressed slowly. This patient underwent a final examination in our department in her 40s, at which time her creatinine level was 3.4 mg/dL. In all 4 cases, no evidence of vascular or glomerular disease was identified.

DISCUSSION

We report clinical characteristics, kidney prognosis, and histopathologic findings of patients with anorexia nervosa treated by nephrologists. Median age at diagnosis with anorexia nervosa was 19.5 years, and that at the first visit to a nephrologist was 39.0 years, an interval of 20 or more years. At the first visit to a nephrologist, most patients showed various degrees of kidney disease, a small BSA, and hypokalemia. In patients with anorexia nervosa, eGFR and BMI have been reported to be significantly correlated, implying that being extremely underweight promotes decreased kidney function.

Serum potassium levels were low in most patients included in this study. Hypokalemia is one of the most frequent and serious consequences of anorexia nervosa, with an estimated prevalence of approximately 20%. In general, serum potassium levels increase as chronic kidney disease progresses. However, serum potassium levels are paradoxically decreased in patients with anorexia nervosa, even those with advanced kidney disease. Hypokalemia in anorexia nervosa may be due to a deficit in potassium intake, habitual vomiting, and abuse of diuretics or laxatives. The renin-angiotensin-aldosterone system is upregulated in response to a persistent decrease in serum potassium levels, which may further contribute to the maintenance of hypokalemia in anorexia nervosa. Magnesium levels were high in some patients with anorexia nervosa included in this study, especially patients with advanced kidney disease. The use of magnesium-containing laxatives may be associated with a risk for hypermagnesemia.

Four of the patients underwent kidney biopsy. Among them, a patient with preserved kidney function showed hypertrophy of the juxtaglomerular apparatus, but 3 patients with moderate to advanced kidney disease did not. Hypertrophy of the juxtaglomerular apparatus may reflect hyper-reninemia due to a long-term decrease in chloride concentration in the macula densa, suggesting that this patient had a condition involving loss of salt from the kidney. Our findings indicate that over the long term such a state blunts the feedback mechanism that mediates histopathologic renormalization of the juxtaglomerular...

| Table 3. Clinical and Histopathologic Findings at Biopsy |

| Case 1 | Case 2 | Case 3 | Case 4 |
|--------|--------|--------|--------|
| **Clinical findings** | | | |
| Age at biopsy, y | 30s | 30s | 30s | 20s |
| Reasons for renal biopsy indication | Elevated tubulointerstitial marker, hypokalemia | Unknown renal dysfunction | Unknown renal dysfunction | Rapidly progressing renal dysfunction, hypokalemia |
| Duration from development of an eating disorder to biopsy, y | 0 | 9 | 14 | 10 |
| BMI, kg/m² | 17.6 | 13.9 | 14.6 | 14.9 |
| BSA, m² | 1.44 | 1.30 | 1.26 | 1.19 |
| Serum creatinine, mg/dL | 0.59 | 3.83 | 2.99 | 1.4 |
| eGFR, mL/min/1.73 m² | 94 | 13 | 16 | 40 |
| Serum potassium, mmol/L | 2.8 | 2.9 | 3.3 | 2.1 |
| Serum magnesium, g/dL | 2.1 | 2.3 | 1.8 | 5.2 |
| pH | 7.478 | 7.471 | 7.403 | 7.436 |
| HCO₃⁻, mmol/L | 32.4 | 39.4 | 20.6 | 26.9 |
| **Histopathologic findings** | | | |
| IF/TA, % | 5 | 50 | 60 | 30 |
| Calcification | NA | NA | NA | + |
| Cortex medulla ratio | 9:1 | 9:1 | 8:2 | 10:0 |
| Glomerular number | 47 | 35 | 37 | 146 |
| GGS, % | 2 | 23 | 43 | 3 |
| Hypertrophy of JGA | + | ± | – | – |
| **Note:** Conversion factors for units: creatinine in mg/dL to μmol/L, ×88.4. Abbreviations: BMI, body mass index; BSA, body surface area; eGFR, estimated glomerular filtration rate; GGS, global glomerular sclerosis; IF/TA, interstitial fibrosis and/or tubular atrophy; JGA, juxtaglomerular apparatus; NA, not available. |
Figure 1. Kidney histopathologic findings. (A) Case 1: a woman in her 30s with normal kidney function exhibited hyperplasia of the juxtaglomerular apparatus (periodic acid–Schiff staining; original magnification, ×400). (B) Case 1: tubulointerstitium damage was mild (interstitial fibrosis and/or tubular atrophy < 5%). (C) Case 2: a woman in her 30s with severely decreased kidney function; interstitial expansion and inflammation were found (B, C: Masson trichrome staining; original magnification, ×100). (D) Case 2: most infiltrating cells in the tubulointerstitium were mononuclear cells (hematoxylin and eosin staining; original magnification, ×200). (E) Case 3: a woman in her 30s with severely decreased kidney function showed marked tubulointerstitial damage with cast formation and global glomerulosclerosis (periodic acid–Schiff staining; original magnification, ×100). (F) Most glomeruli showed global glomerulosclerosis of the obsolescence type (Masson trichrome staining; original magnification, ×100). (G) Case 4: a woman in her 20s with moderately decreased kidney function. Analyses of kidney biopsy specimens showed that most glomeruli on the surface layer of the renal cortex were collapsed (Masson trichrome staining; original magnification, ×50). (H) Case 4: enlargement of the boxed area in G (Masson trichrome staining; original magnification, ×100).
apparatus. A patient with kidney disease exhibited glomerular collapse or global glomerulosclerosis on the surface layer of the renal cortex together with the tubulointerstitial injuries. These findings are consistent with the notion that the kidney disease was caused by chronic ischemia and/or electrolyte disorders.

Persistence of chronic hypokalemia is hypothesized to cause tubulointerstitial damage, renal tubular fibrosis, atrophy, and cyst formation, but the causal relationship between chronic hypokalemia and anorexia nervosa has not been established. In an experimental model, chronic hypokalemia results in kidney ischemia and subsequent tubular injury due to accumulation of ammonium from urea.19

Global glomerulosclerosis is classified as the solidification or obsolescence type.20 The former is caused by expansion of the mesangial matrices and relative condensation of the glomerular capillaries, while the latter reflects glomerular shrinkage and collapse due to ischemia. In this study, 3 of 4 patients showed marked global glomerulosclerosis, all of the obsolescence type. Patients with anorexia nervosa tend to repeatedly self-induce vomiting and abuse diuretics and laxatives due to extreme body dysmorphia. This can induce kidney ischemia, followed by chronic kidney injury and irreversible sclerotic and fibrotic changes in the kidneys.

Our findings have implications for daily clinical practice in nephrology. First, patients with anorexia nervosa should be referred to nephrologists at an earlier stage of kidney disease; that is, before irreversible kidney injury occurs. To this end, close collaboration between psychiatrists and nephrologists may be required. Second, education is required for patients with anorexia nervosa regarding the risks of abusing diuretics or laxatives and the need for adequate hydration to protect the kidneys from ischemic and/or hypokalemic injury. Third, a kidney biopsy should be considered in some patients with anorexia nervosa with kidney disease to confirm histopathologically that the kidney injury is induced by anorexia nervosa.

The strength of this study is that it is one of a few to focus on the clinical and histopathologic features of patients with anorexia nervosa from the viewpoint of nephrologists.10,11 In addition, the long-term follow-up enabled us to compare patient characteristics according to kidney outcomes.

However, this study also had several limitations. First, this was a retrospective observational study in limited facilities and may have included various biases. Therefore, it is difficult to generalize our observations to all patients with anorexia nervosa. Large-scale studies of patients with anorexia nervosa, including those in the early stages of disease, are required.

Second, kidney function was assessed based on creatinine level, which may have led to overestimation of kidney function, because patients with anorexia nervosa have less muscle mass than healthy people. In future studies, kidney function should be evaluated using metrics not influenced by muscle mass, such as measured GFR or eGFR by cystatin C level. Although measured GFR is the gold standard for assessing kidney function, we could not obtain these data in most of our patients. Estimating GFR based on cystatin C level may be helpful as an alternative method because cystatin C is less affected by muscle mass than creatinine.21

Third, anorexia nervosa was diagnosed based on the medical records of psychiatrists, not using criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Characteristics of all patients were consistent with those typical of anorexia nervosa, but we were unable to determine their anorexia nervosa subtypes (eg, the casual–eating–excretion and restriction subtypes).

In conclusion, the 14 patients with anorexia nervosa in this study showed relatively severe and irreversible kidney disease at the first visit to a nephrologist. Therefore, improving kidney outcomes of patients with anorexia nervosa–associated kidney disease may require earlier intervention by nephrologists.

ARTICLE INFORMATION

Authors’ Full Names and Academic Degrees: Hirokazu Marumoto, MD, Takaya Sasaki, MD, Nobuo Tsuboi, MD, PhD, Tatsuhiko Ito, MD, PhD, Masahiro Ishikawa, MD, PhD, Makoto Ogura, MD, PhD, Masato Ikeda, MD, PhD, and Takashi Yokoo, MD, PhD.

Authors’ Affiliations: Division of Nephrology and Hypertension, Department of Internal Medicine (HM, TS, NT, Mishikawa, MO, Mikeda, TY), and Department of Psychiatry (TI), The Jikei University School of Medicine, Tokyo, Japan.

Address for Correspondence: Nobuo Tsuboi, MD, PhD, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minatoku, Tokyo, Japan. E-mail: tsuboi-n@jikei.ac.jp

Authors’ Contributions: Conception and design: HM, TS, and NT; data collection: HM and TS; data analysis: HM, TS, and NT; data interpretation: all authors. TI provided intellectual input regarding the differential diagnosis of psychiatric disorders. HM and TS equally contributed to this work. Each author contributed relevant intellectual content and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Support: None.

Financial Disclosure: The authors declare that they have no relevant financial interests.

Prior Presentation: Parts of this study were presented at the 61st Annual Meeting of the Japanese Society of Nephrology, June 8-10, 2018, Niigata, Japan.

Peer Review: Received November 5, 2019. Evaluated by 2 external peer reviewers, with direct editorial input from an Associate Editor and the Editor-in-Chief. Accepted in revised form March 25, 2020.

REFERENCES

1. Westmoreland P, Krantz MJ, Mehler PS. Medical complications of anorexia nervosa and bulimia. Am J Med. 2016;129(1):30-37.
2. Curnin L, Schmidt U, Treasure J. Time trends in eating disorder incidence. Br J Psychiatry. 2005;186:132-135.
3. Hoek HW, van Hoeken D. Review of the prevalence and incidence of eating disorders. Int J Eat Disorders. 2003;34:383-396.
4. Lock JD, Fitzpatrick KK. Anorexia nervosa. BMJ Clin Evid. 2009;10:1011-1128.
5. Brotman AW, Sterill TA, Brotman DL. Renal disease and dysfunction in two patients with anorexia nervosa. J Clin Psychiatry. 1986;47:433-434.
6. Palla B, Litt IF. Medical complications of eating disorders in adolescents. Pediatrics. 1988;81:613-623.
7. Zipfel S, Löwe B, Reas DL. Long-term prognosis in anorexia nervosa: lessons from a 21-year follow-up study. Lancet. 2000;355:721-722.
8. Reungjui S, Roncal CA, Sato W, et al. Hypokalaemic nephropathy is associated with impaired angiogenesis. J Am Soc Nephrol. 2008;19:125-134.
9. Wada S, Nagase T, Koike Y. A case of anorexia nervosa with acute renal failure induced by rhabdomyolysis; possible involvement of hypophosphatemia or phosphate depletion. Intern Med. 1992;31:478-482.
10. Sonoda M, Wakabayashi K, Tamura N. Renal dysfunction in patients with eating disorders. Jpn J Psychosom Med. 2016;56:453-459.
11. Herzog W, Deter HC, Fiehn W. Medical findings and predictors of long-term physical outcome in anorexia nervosa: a prospective, 12-year follow-up study. Psychol Med. 1997;27:269-279.
12. Matsuo S, Imai E, Horio Y, et al. on behalf of the collaborators for developing Japanese equation for estimating GFR. The Japanese equations for estimating glomerular filtration rate from serum creatinine. Am J Kidney Dis. 2009;53:982-992.
13. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863-871.
14. Levey AS, deJong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17-28.
15. Solez K, Colvin RB, Racusen LC, et al. Banff 2005 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant. 2007;7:518-526.
16. Miller KK, Grinspoon SK, Ciampa J, Hier J, Herzog D, Klibanski A. Medical findings in outpatients with anorexia nervosa. Arch Intern Med. 2005;165:561-566.
17. Randall RE Jr, Cohen MD, Spray CC Jr. Hypermagnesemia in renal failure. Etiology and toxic manifestations. Ann Intern Med. 1964;61:73-88.
18. Taugner R, Waldherr R, Seyberth HW, et al. The juxtaglomerular apparatus in Bartter’s syndrome and related tubulopathies. An immunocytochemical and electron microscopic study. Virchows Arch A Pathol Anat Histopathol. 1988;412:459-470.
19. Tolins JP, Hostetter MK, Hostetter TH. Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. J Clin Invest. 1987;79:1447-1458.
20. Hughson MD, Johnson K, Young RJ. Glomerular size and glomerulosclerosis: relationships to disease categories, glomerular solidification, and ischemic obsolescence. Am J Kidney Dis. 2002;39:679-688.
21. Delanaye P, Cavalier E, Radermecker RP, et al. Estimation of GFR by different creatinine- and cystatin-C-based equations in anorexia nervosa. Clin Nephrol. 2009;71(5):482-491.